AUTHORS
Rhys Richmond, Satoko Ito, MD, PhD2, Manraj Sra, MD3, Sam Hirniak, PhD4, Ding Quan Ng, PhD5, Robert Bona, MD6, Adam Cuker, MD, MS7, George Goshua, MD, SM8
AFFILIATIONS
1 Yale Cancer Center & Yale School of Medicine, New Haven, United States
2 Yale Cancer Center & Yale School of Medicine, New Haven, United States
3 Yale Cancer Center & Yale School of Medicine, New Haven, United States
4 Yale Cancer Center & Yale School of Medicine, New Haven, United States
5 Yale Cancer Center & Yale School of Medicine, New Haven, United States
6 Yale Cancer Center & Yale School of Medicine, New Haven, United States
7 University of Pennsylvania, Philadelphia, United States
8 Yale Cancer Center & Yale School of Medicine, New Haven, United States
ABSTRACT
Introduction: Factor VIII prophylaxis remains the standard of care in severe hemophilia A, but it retains several weaknesses: frequent intravenous infusions, persistent risk of inhibitor development, and significant per-patient costs. Non-factor therapies address these limitations, each with a distinct risk-benefit profile. Fitusiran is the first small interfering RNA therapeutic in hemophilia, lowering antithrombin to restore thrombin generation and rebalance hemostasis independent of coagulation. In the phase 3 ATLAS-PPX trial, participants transitioning from established factor prophylaxis to fitusiran achieved significant reductions in annualized bleeding rate. Fitusiran was approved in March 2025 for hemophilia A or B irrespective of inhibitor status, using an antithrombin-based dose regimen (AT-DR) developed after thrombotic events prompted revision of the original monthly regimen, permitting dosing every two months. Whether this justifies its price is unknown. We discuss an independent cost-effectiveness analysis of fitusiran versus standard care in severe hemophilia A.
Methods: We developed a Markov cohort model of the lifetime cost-effectiveness of fitusiran prophylaxis compared with factor VIII prophylaxis in previously treated patients with severe hemophilia A without inhibitors. Efficacy inputs came from the non-inhibitor cohort of the phase 3 ATLAS-PPX trial, where patients transitioned from prior clotting factor concentrate prophylaxis to fitusiran. Standard half-life (SHL) prophylaxis was the base-case comparator and scenario analysis evaluated extended half-life (EHL)prophylaxis. Fitusiran dosing reflected the approved AT-DR, with a 245.6 mg annual maintenance dose per the US label. Costs originated from the Centers for Medicare & Medicaid Services, supplemented with chronic arthropathy and post intracranial hemorrhage (ICH) utilization literature. Breakthrough bleed factor use applied trial-observed per-bleed dosing, with expert-validated dosing for ICH and major surgery. Quality of life was parameterized with two approaches, both quantifying in quality-adjusted life years (QALYs) as follows: (1) base-case analysis using ATLAS-PPX trial-specific utilities from fitusiran-treated patients, with (2) additional scenario analysis applying assuming complete target joint resolution with fitusiran using age-dependent hemophilia-specific utilities. Internal validation was conducted against ATLAS-PPX annual bleeding events. Analyses took a US healthcare system perspective across all accepted US willingness-to-pay (WTP) thresholds, with a base-case WTP of $120,000/QALY. The primary outcome was the incremental cost-effectiveness ratio (ICER), or its reformulation the incremental net monetary benefit (iNMB). Secondary outcomes includedthreshold analyses for parameters at which conclusions could change. Probabilistic sensitivity analyses captured uncertainty in all parameters over 10,000 Monte Carlo iterations.
Results: Projected annualized bleeding rates (ABRs) were 3.11 (ATLAS-PPX: 3.2) and 5.66 (ATLAS-PPX: 5.9) in the fitusiran and FVIII arms, respectively. In the base case, fitusiran and SHL accrued 21.52 and 20.03 discounted QALYs at discounted costs of $21.1 and $18.2 million, with an ICER of $1,929,000/QALY gained (95% credible interval [CI]: $1.4-2.6 million/QALY). In scenario analysis assuming complete target joint resolution with fitusiran, the two arms accrued 21.15 and 18.38 QALYs, with an incremental 2.77 QALYs and an ICER of $1,012,000/QALY (95% CI: $0.7-$1.4 million/QALY). Compared fitusiran with EHL FVIII prophylaxis, the lifetime cost of the FVIII arm increased to $27.1 million, making fitusiran the dominant strategy, with an iNMB of $6,199,000 (95% CI: $5.7-6.7 million). Threshold analyses showed fitusiran could be cost-effective at 1) weekly SHL dosing that exceeds 102 IU/kg, 2) at body weights of >115% age-dependent population median or 3) a 13% price reduction for fitusiran. Across sets of 10,000 second-order Monte Carlo iterations, 1) SHL was favored over fitusiran in 100%, and 2) fitusiran was favored over EHL in 100%.
Conclusion: Compared with FVIII prophylaxis, fitusiran improved quality-adjusted life expectancy and reduced FVIII consumption for breakthrough bleeding. At current pricing, fitusiran is not cost-effective versus SHL prophylaxis at accepted US WTP thresholds and is cost-saving versus EHL prophylaxis.
DISCLOSURES
Rhys Richmond: No relevant conflicts of interest to declare.